Technical Analysis: 4-Hydrazinobenzenesulfonamide Coa And Purity Specs

• Strict adherence to ≥98% assay standards for pharmaceutical grading.
• Comprehensive COA documentation covering residual solvents and heavy metals.
• Reliable bulk supply chains optimized for Celecoxib intermediate production.

In the pharmaceutical manufacturing sector, the integrity of key intermediates dictates the quality of the final active pharmaceutical ingredient (API). For manufacturers producing COX-2 inhibitors, specifically Celecoxib, the quality of 4-Hydrazinobenzenesulfonamide (CAS: 4392-54-5) is paramount. This technical dossier outlines the critical Certificate of Analysis (COA) parameters, purity specifications, and process controls required for industrial-scale procurement.

Understanding Certificate of Analysis (COA) Requirements

A robust COA is the primary document verifying chemical identity and quality compliance. For bulk buyers, a standard COA must extend beyond simple identity confirmation. It should provide quantitative data on assay purity, residual solvents, and specific impurities that could interfere with downstream cyclization reactions. When evaluating suppliers, procurement managers must ensure the documentation aligns with international pharmacopoeia standards.

Key parameters typically scrutinized during quality assurance audits include:

• Assay (HPLC/GC): Confirmation of main component percentage, typically requiring ≥98.0% for high-grade synthesis.
• Related Substances: Identification of process impurities such as unreacted starting materials or over-sulfonated byproducts.
• Residual Solvents: Compliance with ICH Q3C guidelines regarding Class 1, 2, and 3 solvents.
• Heavy Metals: Verification that lead, arsenic, and mercury levels are within safe limits for pharmaceutical use.

At NINGBO INNO PHARMCHEM CO.,LTD., every batch undergoes rigorous testing to ensure these parameters are met before release. This level of scrutiny minimizes batch failure rates during the subsequent synthesis of Celecoxib.

Key Quality Indicators: Assay, Residual Solvents, and Impurities

The chemical stability and reactivity of p-Hydrazinobenzenesulfonamide are directly influenced by its purity profile. Impurities can act as catalyst poisons or introduce side reactions during the condensation step with diketones. Therefore, industrial purity specifications must be tightly controlled.

Assay and Chromatographic Profile

High-performance liquid chromatography (HPLC) is the standard method for determining assay strength. A typical specification requires a minimum area normalization of 98.0%. Peaks corresponding to hydrazine hydrate residues or sulfonamide degradation products must be quantified. Suppliers offering lower purity grades often compromise on the synthesis route, leading to higher impurity loads that are difficult to purge in later steps.

Residual Solvent Management

Given the solubility profile of this intermediate, crystallization often involves polar solvents. It is critical that the final product is free from excessive moisture and organic volatiles. Karl Fischer titration is commonly employed to measure water content, with a typical limit of <0.5% to prevent hydrolysis during storage. Gas chromatography (GC) headspace analysis confirms the absence of prohibited solvents.

Ensuring ≥98% Purity for Celecoxib Intermediate Applications

The transformation of this sulfonamide into Celecoxib requires precise stoichiometry. Variations in purity can lead to inconsistent reaction yields and difficult purification workflows. Manufacturers seeking a competitive bulk price must balance cost against the technical risk of lower-grade materials. Investing in higher purity intermediates often reduces overall production costs by minimizing waste and rework.

When sourcing high-purity 4-Hydrazinobenzenesulfonamide, buyers should verify the supplier's capacity to maintain consistent quality across large volumes. Consistency is key for validating regulatory filings and ensuring supply chain reliability.

Technical Specification Table

The following table outlines the standard technical specifications expected for pharmaceutical-grade material suitable for Celecoxib production.

Parameter	Specification Standard	Test Method
Appearance	White to Off-White Crystalline Powder	Visual
Assay (Dry Basis)	≥ 98.0%	HPLC
Loss on Drying	≤ 0.5%	Karl Fischer / LOD
Residue on Ignition	≤ 0.1%	Gravimetric
Heavy Metals	≤ 10 ppm	ICP-MS / AAS
Related Substances	Single Impurity ≤ 0.1%, Total ≤ 0.5%	HPLC

Manufacturing Process and Supply Chain Stability

The production of 4-AMINOSULFONYLPHENYLHYDRAZINE involves careful control of sulfonation and hydrazination steps. Variations in temperature or reagent addition rates can impact the industrial purity of the final crop. A reliable global manufacturer must demonstrate control over these critical process parameters to ensure batch-to-batch consistency.

Supply chain resilience is another critical factor. Disruptions in raw material availability can affect lead times and bulk price stability. Established partners maintain strategic stockpiles and diversified raw material sources to mitigate these risks. This ensures that pharmaceutical producers can maintain continuous operation without interruption.

Conclusion and Procurement Recommendations

Selecting the right intermediate supplier is a strategic decision that impacts both regulatory compliance and production efficiency. The COA serves as the contract of quality between the buyer and the manufacturer. It is essential to partner with a supplier who transparently shares detailed analytical data and maintains robust quality management systems.

For manufacturers requiring consistent, high-quality intermediates for Celecoxib synthesis, NINGBO INNO PHARMCHEM CO.,LTD. stands as a premier global manufacturer offering these technical advantages and bulk supply. By prioritizing verified purity specs and comprehensive documentation, pharmaceutical companies can secure their production lines against quality variations and ensure the successful delivery of life-saving medications.